Home Newsfeeds JMP Securities Reiterates Market Outperform on Amazon.com, Maintains $140 Price Target

JMP Securities Reiterates Market Outperform on Amazon.com, Maintains $140 Price Target

JMP Securities analyst Nicholas Jones reiterates Amazon.com (NASDAQ:AMZN) with a Market Outperform and maintains $140 price target.

byBenzinga Newsdesk

February 3, 2023

1 minute read

JMP Securities analyst Nicholas Jones reiterates Amazon.com (NASDAQ:AMZN) with a Market Outperform and maintains $140 price target.

Microsoft’s $69B Bid To Acquire Activision Blizzard Receives European Union Approval

By Franca Quarneti

May 15, 11:59 AM

The European Union's antitrust regulator has given its approval Monday to Microsoft Corporation's (NASDAQ: MSFT) proposed $68.7-billion ac

ATVI

Iovance Biotherapeutics Prices $211M Underwritten Offering of Common Stock to Support the Commercial Launch of AMTAGVI

By Benzinga Newsdesk

February 20, 7:34 AM

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte

IOVA

eFFECTOR Therapeutics Announces 1-For-25 Reverse Stock Split, Will Become Effective At 12:01 A.M. Eastern Time, On January 12, 2024.

By Benzinga Newsdesk

January 9, 9:10 AM

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors ("STRIs") for the treatment of cancer, today announced that its Board of Directors (the "Board") has

EFTR

Yahoo To Let Go 20% Employees, Focus On Its Flagship Ad Business

By Anusuya Lahiri

February 10, 10:19 AM

Apollo Global Management, Inc's (NYSE: APO) Yahoo weighed downsizing over 20% of its total workforce as part of its ad tech division overhaul.

APO

JMP Securities Reiterates Market Outperform on Amazon.com, Maintains $140 Price Target

Related Posts

Microsoft’s $69B Bid To Acquire Activision Blizzard Receives European Union Approval

Iovance Biotherapeutics Prices $211M Underwritten Offering of Common Stock to Support the Commercial Launch of AMTAGVI

eFFECTOR Therapeutics Announces 1-For-25 Reverse Stock Split, Will Become Effective At 12:01 A.M. Eastern Time, On January 12, 2024.

Yahoo To Let Go 20% Employees, Focus On Its Flagship Ad Business